Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2070610 | 0.84 | CYP19A1 (0.54) | CYP19A1SIGMAR1PLAU | |
| SCHEMBL17956326 | 0.80 | IDO1 (0.53) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL28138448 | 0.75 | MTNR1A (0.55) | IDO1CYP19A1ADRA2A | |
| SCHEMBL29593942 | 0.74 | HTR2A (0.52) | IDO1CYP19A1ADRA2APLAU | |
| SCHEMBL29447948 | 0.74 | IDO1 (0.47) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL1800050 | 0.74 | IDO1 (0.47) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL22052056 | 0.74 | IDO1 (0.47) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL835059 | 0.74 | IDO1 (0.47) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL9933773 | 0.74 | IDO1 (0.47) | IDO1CYP19A1ADRA2ASIGMAR1DRD3 | |
| SCHEMBL714536 | 0.74 | HTR2A (0.52) | IDO1CYP19A1ADRA2APLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100358514-C | Remedies for allergic eye diseases | NIKKEN CHEMICALS CO LTD (JP) | 2008-01-02 | — | — | CN | claimed |
| EP-0994100-B1 | 3-ANILINO-2-CYCLOALKENONE DERIVATES | NIKKEN CHEMICALS CO LTD (JP) | 2006-08-30 | — | — | EP | claimed |
| US-20040220227-A1 | Remedies for allergic eye diseases | NIKKEN CHEMICALS CO., LTD. (JP) | 2004-11-04 | — | — | US | claimed |
| CN-1525854-A | Remedies for allergic eye diseases | 日研化学株式会社 | 2004-09-01 | — | — | CN | claimed |
| EP-1410795-A1 | REMEDIES FOR ALLERGIC EYE DISEASES | Nikken Chemicals Company, Limited (JP) | 2004-04-21 | — | — | EP | claimed |
| US-6235736-B1 | ANTIINFLAMMATORY AGENTS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-05-22 | — | — | US | claimed |
| EP-0994100-A1 | 3-ANILINO-2-CYCLOALKENONE DERIVATES | Nikken Chemicals Company, Limited (JP) | 2000-04-19 | — | — | EP | claimed |
| EP-3050889-B1 | ALKYL TIN COMPOUND | ASAHI CHEMICAL IND (JP) | 2020-10-28 | — | — | EP | disclosed |
| CN-105579461-B | Alkyl tin compound | 旭化成株式会社 | 2020-02-14 | — | — | CN | disclosed |
| US-9844775-B2 | Alkyl tin compound | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2017-12-19 | — | — | US | disclosed |
| US-20160228863-A1 | Alkyl Tin Compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3050889-A1 | ALKYL TIN COMPOUND | Asahi Kasei Chemicals Corporation (JP) | 2016-08-03 | — | — | EP | disclosed |
| CN-101014576-B | Aryl spirolactam cgrp receptor antagonists | MERCK & CO INC | 2011-05-25 | — | — | CN | disclosed |
| US-6265402-B1 | ANTIINFLAMMATORY AGENTS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| US-6235736-B1 | ANTIINFLAMMATORY AGENTS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0994100-A1 | 3-ANILINO-2-CYCLOALKENONE DERIVATES | Nikken Chemicals Company, Limited (JP) | 2000-04-19 | — | — | EP | disclosed |
| US-6051718-A | A PHOSPHODIESTERASE ENZYME INHIBITOR AND A CYTOKINE ANTAGONIST FOR TREATING ALLERGIC, ATOPIC AND INFLAMMATORY DISEASES INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2000-04-18 | — | — | US | disclosed |
| EP-0934280-A1 | PDE IV INHIBITING 2-CYANOIMINOIMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-08-11 | — | — | EP | disclosed |
| EP-0924204-A1 | 2-PHENYLMORPHOLIN-5-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Nikken Chemicals Company, Limited (JP) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998014432-A1 | PDE IV INHIBITING 2-CYANOIMINOIMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220227-A1 | Remedies for allergic eye diseases | HRH2, HRH1, HRH4 | IDO1 217/4885CYP19A1 473/4885ADRA2A 463/4885 |
| US-20160228863-A1 | Alkyl Tin Compound | TERT, MYC, ABL1 | IDO1 2185/4885CYP19A1 2133/4885ADRA2A 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.